Marleen Kars


Affiliation: Leiden University Medical Center
Country: The Netherlands


  1. Kars M, Roelfsema F, Romijn J, Pereira A. Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol. 2006;155:523-34 pubmed
    ..For pituitary tumors that exhibit high mitotic activity, increased Ki-67 and/or p53 immunoreactivity, it may be useful to denote these tumors as 'atypical' prolactinomas to raise the possibility of future malignant development. ..
  2. Kars M, van der Klaauw A, Onstein C, Pereira A, Romijn J. Quality of life is decreased in female patients treated for microprolactinoma. Eur J Endocrinol. 2007;157:133-9 pubmed
    ..We evaluated this topic in female patients with microprolactinoma, because other pituitary adenomas are associated with decreased quality of life...
  3. Kars M, Delgado V, Holman E, Feelders R, Smit J, Romijn J, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008;93:3348-56 pubmed publisher
    ..The aim of the present study was to assess the prevalence of valvular heart disease in patients treated with dopamine agonists for prolactinomas...
  4. Kars M, Pereira A, Smit J, Romijn J. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med. 2009;20:387-93 pubmed publisher
    ..Dopamine agonists are the first line therapy for the treatment of prolactinomas. The aim of this study was to assess the outcome of macroprolactinomas during long-term follow-up after initial treatment with dopamine agonists...